reports
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: ...
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva’...
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcar...
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference – Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Expects Operating Expenses of Between $210 Million and $2...
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Zymeworks Outlines Strategic Priorities and Outlook for 2026 Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and ChinaCompany well-positioned to execute new strategy compounding long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation$125.0 million share repurchase plan ann...
Royalty Pharma and Teva Enter Agreement to Accelerate Development of P...
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -...
Teva and Royalty Pharma Enter Agreement to Accelerate Development of P...
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- ...
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease an...
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026 Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced ...
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI ...
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones – Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from first commercial sale on November 21, 2025, through December 31, 2025 – – Company poised for breakthrough progress in 2026 with deep pipeline of potentially transformative therapies – SAN DIEGO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical ...
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Pro...
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicate...
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th An...
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026 Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR t...
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and ...
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results 2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide pati...
- ABGSC Renewable Energy Research
- Daniel Vårdal Haugland
Exagen Inc. Announces Select Preliminary 2025 Financial Results
Exagen Inc. Announces Select Preliminary 2025 Financial Results CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance. Select Preliminary Unaudited 2025 Results Revenue Three Months EndedDecember 31, 2025 Twelve Months EndedDecember 31, 2025Total Revenue$16M to $17M $66M to $67MYear-Over-Year Growth17% to 24% 19% to 20% Other Twelve Months EndedDecember 31, 2025...
Molecular Partners Highlights Clinical Development Progress and Antici...
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026Phase 2 investigator-initiated trial of MP0317 now open with patient dosing ongoing, exploring MP0317 in combination with standard-of-care for patients with cholangiocarcinomaPhase 1/2a trial of multi-specific T cell engager MP0533 on...
- ABGSC Consumer Goods Research
- Benjamin Wahlstedt
- Mikkel Kousgaard Rasmussen
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan He...
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company’s strategic vision to drive the next stage of growth of its rare diseas...
- ABGSC Credit Research
- Bendik Fougner Engebretsen
- ABGSC Energy Research
- John Olaisen
Commerce Supports Universal Commerce Protocol, Plans to Offer Buying D...
Commerce Supports Universal Commerce Protocol, Plans to Offer Buying Directly Across Google’s AI Surfaces New standard creates a common language for agents and systems across the entire shopping journey from discovery and buying to post-purchase experiences AUSTIN, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Commerce (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of leading ecommerce platform BigCommerce and data feed optimization leader Feedonomics, today announced its endorsement of Google’s new (UCP). The new, open-source standard creates...
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New...
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition. Preliminary Unaudited Fourth Quarter and Full-yea...
Benitec Biopharma Provides Positive Long-Term Clinical Study Results f...
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response • Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.